The development of a Glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma-Reference-Cited by-同舟云学术

The development of a Glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma

Published:2020 Issue:20 Volume:8 Page:5656-5665
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Qin Yushuang¹²³⁴⁵,Cheng Siyuan¹²³⁴⁵,Li Yesen⁶⁷⁸⁹,Zou Sijuan¹²³⁴⁵,Chen Minglong⁶¹⁰¹¹¹²⁹,Zhu Dongling¹²³⁴⁵,Gao Shi⁶¹⁰¹¹¹²⁹,Wu Hua⁶⁷⁸⁹,Zhu Lei¹³¹⁴¹⁵¹⁶^ORCID,Zhu Xiaohua¹²³⁴⁵

Affiliation:

1. Department of Nuclear Medicine and PET

2. Tongji Hospital

3. Tongji Medical College

4. Huazhong University of Science and Technology

5. Wuhan 430000

6. Department of Nuclear Medicine

7. The First Affiliated Hospital of Xiamen University

8. Xiamen 361003

9. China

10. China-Japan Union Hospital

11. Jilin University

12. Changchun 130033

13. Departments of Surgery

14. Emory University School of Medicine

15. Atlanta

16. USA

Abstract

An in vivo and in vitro two-step phage display screening approach to identify Glypican-3 targeting peptides for the detection of hepatocellular carcinoma with low normal liver uptake.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hubei Province

Department of Science and Technology of Jilin Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2020/BM/D0BM00943A

Reference31 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries